Welcome to our dedicated page for Incyte SEC filings (Ticker: INCY), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Incyte Corporation's SEC filings document a Nasdaq-listed biopharmaceutical issuer with common stock trading under INCY and product franchises in hematology, oncology, and inflammation and autoimmunity. Form 8-K reports cover operating results, product sales trends for Jakafi and Opzelura, financial guidance, pipeline updates, and regulatory correspondence affecting drug applications.
Proxy and current-report filings also disclose board and executive changes, officer appointments, equity compensation, shareholder voting matters, executive pay, governance practices, and registered security information. These filings frame Incyte's capital structure, leadership oversight, commercial portfolio, clinical-development programs, and regulatory risks.
On 26 June 2025, Incyte Corporation (NASDAQ: INCY) filed a Form 4 reporting an insider transaction by Chief Executive Officer and Director William Meury. The filing discloses a grant of 110,630 employee stock options with an exercise price of $70.81 per share. The options vest 25 % after one year, with the remaining 75 % vesting in equal monthly installments over the subsequent three years, and expire on 25 June 2035. After this grant, Meury beneficially owns 110,630 derivative securities, held directly. No purchases or sales of common stock were reported, and the transaction is classified as "A" (acquisition). The document was signed on 30 June 2025.
In its Form 8-K dated June 26, 2025, Incyte Corporation (INCY) disclosed a major leadership transition.
Retirement of CEO Hervé Hoppenot: Mr. Hoppenot stepped down as President & Chief Executive Officer effective June 26, 2025, but will remain on the Board and act as special advisor for up to one year. Compensation during the advisory period equals his current $1,395,731 annual base salary for six months and 50% of that rate for the subsequent six months, plus a prorated 2025 cash bonus. He also received equity grants of 6,016 RSUs, 18,438 stock options, and 18,050 performance shares (0-200% payout, 3-year TSR goals), all of which will continue to vest post-transition, subject to customary covenants.
Appointment of William J. Meury as President & CEO: Effective the same date, Mr. Meury (age 57) joins the company and its Board. His background includes CEO roles at Anthos Therapeutics (2024-2025) and Karuna Therapeutics (2023-2024), senior commercial leadership at Allergan, and over 30 years in biopharma commercialization.
Compensation package for Mr. Meury: • Initial base salary $1,250,000 • Target annual bonus 100% of salary (pro-rated for 2025) • Time-based RSUs for 36,101 shares (25% per year over four years) • Options for 110,630 shares (25% after one year, then monthly over 36 months) • 108,303 performance shares (0-200% payout, 3-year TSR goals) • One-time sign-on PSU award for 125,000 shares (0-400% payout tied to multi-year stock-price hurdles) • Relocation and commuting benefits. Severance terms include 1.5× salary+target bonus if terminated without Cause or he resigns for Good Reason outside a change-of-control window, plus partial accelerated vesting of equity.
Governance changes: Lead Independent Director Julian C. Baker becomes Chairman of the Board.
These actions signal a planned but material shift in senior leadership, accompanied by significant equity-based incentives designed to align the incoming CEO with long-term shareholder value.